PR Newswire Clinical TrialsOriginal article
Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA
RegulatoryapprovedZIIHERAPATHWAY HER2 (4B5) testVENTANA HER2 Dual ISH DNA Probe CocktailPositive
AI Analysis
Summary
Roche received FDA approval for two companion diagnostic tests (PATHWAY HER2 (4B5) and VENTANA HER2 Dual ISH DNA Probe Cocktail) designed to identify HER2-positive patients with metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA treatment.
Outcome Details
FDA approval for companion diagnostic tests PATHWAY HER2 (4B5) and VENTANA HER2 Dual ISH DNA Probe Cocktail
Importance:7/10
Sentiment:
0.85
FDA approvalcompanion diagnosticHER2-positivegastric canceresophageal canceroncology
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 26, 2026 6:52 PM